Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Study to Evaluate the Efficacy, Safety and PK of a Combination of Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate for Treatment of HIV-1 Infection in Patients With Drug Susceptible-TB on a Rifampicin-based Regimen

NCT04734652 is registered in ClinicalTrials.gov with Centre for the AIDS Programme of Research in South Africa as lead sponsor.

NCT NCT04734652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04734652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Study to Evaluate the Efficacy, Safety and PK of a Combination of Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate for Treatment of HIV-1 Infection in Patients With Drug Susceptible-TB on a Rifampicin-based Regimen
Lead sponsor
Centre for the AIDS Programme of Research in South Africa
Phase
Phase 2
Overall status
Completed
Start date
February 18, 2022
Completion date
August 31, 2024
Enrollment
122 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv/aids, tuberculosis, pulmonary